IQVIA (NYSE:IQV) Price Target Cut to $265.00 by Analysts at Morgan Stanley

IQVIA (NYSE:IQV) had its price objective decreased by Morgan Stanley from $280.00 to $265.00 in a research note published on Monday morning, Benzinga reports. Morgan Stanley currently has an overweight rating on the medical research company’s stock.

IQV has been the subject of a number of other research reports. UBS Group lifted their price objective on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. BTIG Research lowered their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Price Performance

Shares of NYSE:IQV opened at $221.19 on Monday. IQVIA has a one year low of $190.20 and a one year high of $261.73. The stock has a market cap of $40.15 billion, a PE ratio of 29.03, a price-to-earnings-growth ratio of 2.15 and a beta of 1.51. The business’s fifty day moving average price is $232.31 and its two-hundred day moving average price is $229.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA during the 2nd quarter worth $27,000. Capital Performance Advisors LLP acquired a new position in IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in IQVIA in the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA during the second quarter worth about $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.